Journal of Cancer Research and Therapeutics Close
 

Figure 1: Megakaryocyte immunophenotype in four groups with different cytokine combinations (n = 12). (a) CD34−/CD41+, (b) CD34+/CD41+, (c) CD41+, (d) CD61+, and (e) CD42b+ cell amplification effects. *The cell amplification effect of the thrombopoietin + stem cell factor + FL + interleukin-6 combination was better than the effects of other experiment groups (P < 0.05). On day 14, the total number of the cell subsets was significantly higher than that on day 10 (P < 0.05)

Figure 1: Megakaryocyte immunophenotype in four groups with different cytokine combinations (<i>n</i> = 12). (a) CD34−/CD41+, (b) CD34+/CD41+, (c) CD41+, (d) CD61+, and (e) CD42b+ cell amplification effects. *The cell amplification effect of the thrombopoietin + stem cell factor + FL + interleukin-6 combination was better than the effects of other experiment groups (<i>P</i> < 0.05). <sup>▴</sup>On day 14, the total number of the cell subsets was significantly higher than that on day 10 (<i>P</i> < 0.05)